Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
INSM filed a Form 144 disclosing recent resale notices and issuer stock plan activity. The filing lists multiple issuer plan issuances on 01/04/2026, 01/05/2026, 01/06/2026, 02/01/2026, and 02/24/2026 with amounts of 1,554, 874, 1,312, 786, and 20,248 shares respectively.
The filing also shows sales by Michael Smith on 01/06/2026 (1,396 shares), 01/07/2026 (709 shares), 01/08/2026 (1,053 shares), and 02/04/2026 (640 shares). The excerpt lists 215,551,896 shares outstanding as of 02/24/2026.
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales. On February 19, 2026, he exercised stock options for 6,259 and 4,440 shares, converting them into an equal number of Common Stock shares at grant prices of $30.46 and $17.16 per share.
On the same date, he sold a total of 10,699 Common Stock shares in open-market transactions at weighted average prices between $149.17 and $153.38, under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 4, 2025. After these trades, he held 301,185 shares directly, plus indirect holdings of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
INSM filings report insider stock sales by William Lewis. The filing lists multiple sales dated between 12/04/2025 and 02/19/2026, with reported sale amounts including 13,396, 3,009, 10,699, 19,215, 3,223, 2,357, 4,096, and other similar share quantities. The entries show transaction dates and numeric amounts associated with each sale.
Insmed Incorporated uses this Annual Report to outline its strategy as a global biopharma company focused on respiratory, immunology & inflammation, and neuro & other rare diseases. The company now has two commercial respiratory drugs: ARIKAYCE, an inhaled therapy for MAC lung disease with approvals in the US, Europe and Japan, and BRINSUPRI, an oral treatment for non-cystic fibrosis bronchiectasis approved in the US in August 2025 and by the European Commission in November 2025.
Insmed highlights large addressable markets in bronchiectasis and MAC lung disease and reports positive Phase 3 data for brensocatib (ASPEN) and positive Phase 2 results for TPIP in pulmonary arterial hypertension and PH-ILD, with multiple Phase 3 programs planned in 2026. Early-stage gene therapy programs INS1201 for Duchenne muscular dystrophy and INS1202 for ALS are in Phase 1 trials, while the ARIKAYCE post-marketing ENCORE study is fully enrolled with topline data expected by April 2026 to support potential full US approval and label expansion.
Insmed Incorporated reported strong growth for the fourth quarter and full year 2025 while remaining deeply loss-making and setting ambitious 2026 revenue goals. Total revenue reached $606.4 million in 2025, up from $363.7 million, driven by the U.S. launch of BRINSUPRI and continued ARIKAYCE expansion.
BRINSUPRI generated $144.6 million in Q4 and $172.7 million for 2025, while ARIKAYCE delivered $119.2 million in Q4 and $433.8 million for the year, representing 19% annual growth. Despite this, Insmed posted a 2025 net loss of $1.28 billion, as operating expenses rose to $1.85 billion. The company ended 2025 with approximately $1.4 billion in cash, cash equivalents, and marketable securities and guides for at least $1 billion in 2026 BRINSUPRI revenue and $450–$470 million from ARIKAYCE. Insmed also highlighted Orphan Drug Designation for TPIP in pulmonary arterial hypertension and ongoing late-stage studies. Separately, director David W.J. McGirr will not stand for re-election at the 2026 annual meeting but will continue serving until then.
INSMED Inc. director David W. J. McGirr reported a bona fide gift transfer of 53,400 shares of common stock on February 9, 2026. The filing shows 53,400 shares moved from his direct holdings to indirect ownership through a family trust, leaving 44,323 shares held directly and 53,400 shares held indirectly.
INSMED Inc.’s Chair and CEO William Lewis reported option exercises and share sales on common stock. On February 9, 2026, he exercised stock options for 4,440 shares at $17.16 and 6,259 shares at $30.46 per share, converting them into common stock. The same day, he sold 4,888 shares at a weighted average price of $147.17, 7,221 shares at $148.02, and 1,287 shares at $148.83, under a Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, he directly owned 301,185 common shares and had indirect ownership of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
William Lewis filed a Rule 144 notice to sell 13396 Insmed common shares. The filing lists Merrill Lynch as broker, with the shares to be sold on NASDAQ and an aggregate market value of 1979774. It notes 213273469 common shares outstanding.
The shares to be sold were acquired through stock plan activity, including 10699 shares on 02/09/2026 and 2697 shares on 02/01/2026. The notice also details several prior open-market sales over the past three months with disclosed share counts and gross proceeds.
Insmed Inc.’s Chief Medical Officer, Martina Flammer, M.D., reported a planned stock sale. On 02/05/2026 she sold 869 shares of Insmed common stock at $152.44 per share in a transaction coded as a sale. After this trade, she beneficially owned 83,243 shares directly.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that she adopted on February 27, 2025. Such plans allow insiders to schedule trades in advance, helping separate routine portfolio moves from day-to-day corporate developments.
A holder of common stock in a NASDAQ‑listed company has filed a Form 144 notice to sell 869 shares through Merrill Lynch, with an aggregate market value of $132,462. The filing states that 213,273,469 shares of this class were outstanding and lists an approximate sale date of February 5, 2026.
The securities to be sold were acquired on February 1, 2026 via stock plan activity from the issuer. The person filing, identified in recent sales as Martina Flammer, also sold multiple blocks of common shares between November 11, 2025 and February 3, 2026, with individual trades ranging from hundreds to tens of thousands of shares.